Industry Wants A Breakthrough Therapy, Even Without All The Standards
A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.
You may also be interested in...
With cell and gene therapies becoming more popular, CBER Director Marks says in an interview with the Pink Sheet that more staff may be needed soon.
CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.
A look at the genesis of the US expedited regulatory pathway for drugs and biologics, its benefits, and how the program is working today.